• 1
    Tytgat GN. Shortcomings of the first-generation of proton pump inhibitors. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S2933.
  • 2
    Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S437.
  • 3
    Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 1998; 12: 107989.
  • 4
    Pantoflickova D, Dorta G, Ravic M, Jornod P, Blum AL. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 2003; 17: 150714.
  • 5
    Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RJ. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 5967.
  • 6
    Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159: 64957.
  • 7
    Hémery P, Galmiche JP, Rozé C, et al. Low dose of omeprazole on gastric acid secretion in normal man. Gastroenterol Clin Biol 1987; 11: 14853.
  • 8
    Savarino V, Mela GS, Zentilin P, et al. Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy. Dig Dis Sci 1994; 39: 1618.
  • 9
    Yasuda S. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydoxylation status. Clin Pharm Ther 1995; 58: 14354.
  • 10
    Vanden Branden M, Ring BJ, Binkley SN, Wrighton SA. Interaction of human liver cyto P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics 1996; 6: 8191.
  • 11
    Saitoh T, Fukushima Y, Otsuka H, et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16; 18117.
  • 12
    Katz PO, Hattlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice-daily omeprazole and lansoprazole. Aliment Pharmacol Ther 2000; 14: 70914.
  • 13
    Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122: 62532.
  • 14
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 15
    Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000; 118: 6619.
  • 16
    Isal JP, Zeitoun P, Barbier P, Cayphas JP, Carlsson R. Comparison of two dosage regimens of omeprazole 10 mg once daily and 20 mg weekends as prophylaxis against recurrence of reflux esophagitis. Gastroenterology 1990; 98: A63.
  • 17
    Bardhan KD. Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003; 98(Suppl.): S408.
  • 18
    Lind T, Havelund T, Lundell L, et al. On-demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis – a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999; 13: 90714.
  • 19
    Talley N, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on demand therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 34754.
  • 20
    Tytgat GNJ. Review article: management of mild and severe gastro-oesophageal disease. Aliment Pharmacol Ther 2003; 17(Suppl. 2): 526.
  • 21
    Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S1922.
  • 22
    Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 47382.
  • 23
    Sachs G. Improved on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 1): S3541.
  • 24
    Williams MP, Blanshard C, Millson C, Sercombe J, Pounder RJ. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 2000; 14: 6919.
  • 25
    Tutuian R, Katz PO, Castell DO. Nocturnal acid breakthrough: pH, drugs and bugs. Eur J Gastroenterol Hepatol 2004; 16: 4413.
  • 26
    Gardner JD, Sloan S, Miner PB Jr, Robinson M. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. Aliment Pharmacol Ther 2003; 17: 95564.
  • 27
    Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol 2002; 97: 13329.
    Direct Link:
  • 28
    Bytzer P, Blum AL, de Herdt D. Long-term control of heartburn with on-demand rabeprazole 10 mg in patients with nonerosive reflux disease (NERD). Gut 2003; 52(Suppl. VI): A132.
  • 29
    Bour B, Chousterman M, Labayle D, et al. On-demand therapy with rabeprazole 10 mg (rab 10) as effective long-term management of patients with frequent gastroesophageal reflux symptomatic relapses. Gut 2003; 52(Suppl. VI): A134.